Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Replimune Group, Inc. - Common Stock (NQ:REPL)

9.305 -0.425 (-4.37%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Replimune Group, Inc. - Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Replimune Announces Proposed Public Offering
From Replimune Group Inc
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
S&P 500 Moves Higher; Intuit Shares Fall Following Q1 Results
 
Via Benzinga
Topics Stocks
Crude Oil Gains Over 1%; Ross Stores Earnings Top Views
 
Via Benzinga
Replimune Group: Q3 Earnings Insights
 
Via Benzinga
Barclays Maintains Overweight Rating for Replimune Group: Here's What You Need To Know
 
Via Benzinga
Natural Grocers By Vitamin Cottage, Elastic, Matthews International, Gap And Other Big Stocks Moving Higher On Friday
 
Via Benzinga
Dow Jumps 300 Points; Gap Posts Upbeat Earnings
 
Via Benzinga
Topics Stocks
Replimune Receives Breakthrough Therapy Designation for RP1 and Submits RP1 Biologics License Application to the FDA under the Accelerated Approval Pathway
From Replimune Group Inc
Via GlobeNewswire
Replimune Reports Fiscal Second Quarter 2025 Financial Results and Provides Corporate Update
From Replimune Group Inc
Via GlobeNewswire
Replimune Presents Late-Breaking Abstract Featuring Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024)
From Replimune Group Inc
Via GlobeNewswire
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Replimune Group Inc
Via GlobeNewswire
Replimune to Present at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
From Replimune Group Inc
Via GlobeNewswire
REPL Stock Earnings: Replimune Group Beats EPS for Q1 2025
REPL stock results show that Replimune Group beat analyst estimates for earnings per share the first quarter of 2025. 
Via InvestorPlace
Vail Resorts Posts Downbeat Q3 Results, Joins Concrete Pumping, DocuSign And Other Big Stocks Moving Lower In Friday's Pre-Market Session
 
Via Benzinga
S&P 500 Edges Lower; J. M. Smucker Shares Surge Following Earnings Beat
 
Via Benzinga
Topics Stocks
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Via Benzinga
Why G-III Apparel Shares Are Trading Lower By 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
 
Via Benzinga
Crude Oil Jumps 2%; Lululemon Posts Upbeat Earnings
 
Via Benzinga
Why Is Mid-Cap Cancer-Focused Replimune Stock Trading Higher On Thursday?
Replimune reported that the IGNYTE clinical trial of RP1 plus nivolumab in anti-PD1 failed melanoma showed a 33.6% response rate, with all responses lasting over six months. The treatment was... 
Via Benzinga
J.M. SmuckerPosts Upbeat Earnings, Joins Toro Company, United Natural Foods, Semtech And Other Big Stocks Moving Higher On Thursday
 
Via Benzinga
REPL Stock Earnings: Replimune Group Misses EPS for Q4 2024
REPL stock results show that Replimune Group missed analyst estimates for earnings per share the fourth quarter of 2024. 
Via InvestorPlace
Crude Oil Moves Lower; AutoZone Profit Tops Views
U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite trading higher on Tuesday. The Dow traded down 0.18% to 36,138.19 while the NASDAQ rose 0.19% to 14,212.19. The S&P 500... 
Via Benzinga
Topics Stocks
Why Daktronics Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Daktronics, Inc. (NASDAQ: DAKT) moved lower during Tuesday’s session following weak quarterly results. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga
Dow Falls 100 Points; ISM Services PMI Increases In November
U.S. stocks traded mixed midway through trading, with the Dow Jones index falling around 100 points on Tuesday. The Dow traded down 0.28% to 36,103.52 while the NASDAQ rose 0.32% to 14,230.64. The S&P... 
Via Benzinga
Topics Stocks
Why Is Replimune (REPL) Stock Down 48% Today?
Replimune stock is dropping on Tuesday as investors in REPL shares react to a clinical trial missing both of its primary endpoints. 
Via InvestorPlace
US Stocks Down; JM Smucker Posts Upbeat Earnings
U.S. stocks traded lower this morning, with the Nasdaq Composite falling over 50 points on Tuesday. Following the market opening Tuesday, the Dow traded down 0.23% to 36,120.88 while the NASDAQ fell... 
Via Benzinga
Topics Stocks
What's Going On With Cancer-Focused Replimune Stock Today?
Replimune Group Inc (NASDAQ: REPL) announced results from the primary analysis of the CERPASS trial evaluating RP1 in combination with cemiplimab for locally advanced or metastatic cutaneous  
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback